

Special Issue

Complex Molecular Scenarios in Oncogene-Addicted Non-small Cell Lung Cancer

Message from the Guest Editors

The modern concept of precision oncology implies an integrated histological and molecular approach. The past decade has been transformative for lung cancer management. Since the discovery of *EGFR* mutations, scientific efforts have turned to define molecular subgroups of lung cancer with the aim of unraveling the genomic landscape of this tumor and discovering novel drugs. Although several steps forward have been made, new challenges have emerged. Indeed, with the introduction of targeted molecules in clinical practice, we have become aware of the resistance to such treatments. The widespread use of high-throughput molecular techniques has highlighted increasingly complex molecular scenarios, the development of resistance mechanisms to new generation therapies and the phenotype switch of the original neoplasm. The pathogenetic bases and the prognostic significance of many of these are now known; for others, ongoing and future efforts are required. The aim of this Special Issue is to summarize the knowledge acquired so far and to report new acquisitions on this topic, mainly focusing on the different resistance mechanisms and their therapeutic implications.

Guest Editors

Dr. Federica Pezzuto

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathology Unit, University of Padova, 35121 Padova, Italy

Dr. Francesco Fortarezza

Pathology Unit, University Hospital of Padova, Padua, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/160799

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).